Chimeric Antigen Receptor NK Cell Injection- Pregene Shenzhen Biopharma
Alternative Names: BCMA CAR-NK; Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)Latest Information Update: 07 Apr 2023
At a glance
- Originator Pregene ShenZhen Biotechnology
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 13 Nov 2022 Phase-I clinical trials in Multiple myeloma (In adults, In the elderly, Second-line therapy or greater, Recurrent) in China (Parenteral) (NCT05652530)